Walleye Trading LLC Mirati Therapeutics, Inc. Call Options Transaction History

Walleye Trading LLC

$46.7 Billion
Q3 2024

Call Options

16 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $37,791 - $56,142	-900 Reduced 17.31%	4,300 $252,000
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $25,020 - $40,815	900 Added 20.93%	5,200 $226,000
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $72,260 - $98,980	2,000 Added 86.96%	4,300 $155,000
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $84,042 - $124,798	2,300 New	2,300 $85,000
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $1.93 Million - $2.82 Million	-32,500 Reduced 68.86%	14,700 $1.03 Million
Q2 2022 Aug 08, 2022	BUY	$39.16 - $88.71 $1.54 Million - $3.48 Million	39,200 Added 490.0%	47,200 $3.17 Million
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $37,910 - $75,485	-500 Reduced 5.88%	8,000 $658,000
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $541,241 - $780,189	4,100 Added 93.18%	8,500 $1.25 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $581,372 - $780,780	4,400 New	4,400 $778,000
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $874,059 - $1.22 Million	-5,500 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $891,275 - $1.32 Million	5,500 New	5,500 $1.21 Million
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $626,487 - $1.05 Million	-8,700 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $3.84 Million - $6.39 Million	-55,000 Reduced 86.34%	8,700 $669,000
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $2.6 Million - $4.58 Million	43,700 Added 218.5%	63,700 $6.56 Million
Q1 2019 May 15, 2019	BUY	$43.65 - $78.95 $659,115 - $1.19 Million	15,100 Added 308.16%	20,000 $1.47 Million
Q4 2018 Feb 14, 2019	BUY	$32.0 - $47.43 $156,800 - $232,407	4,900 New	4,900 $208,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.

Account